Trial Profile
A PHASE 1-2 NEOADJUVANT DOSE FINDING, SAFETY, AND IMMUNOLOGIC EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR RECURRENT OVARIAN CANCER AND TUMOR-SPECIFIC INTRANODAL AUTOLOGOUS ALPHA-DC1 VACCINES
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-Bioclones (Primary) ; Rintatolimod (Primary) ; Celecoxib; Cisplatin; Interferon alpha-2b; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2022 According to an AIM ImmunoTech media release, Phase 1 portion of this study is completed.
- 17 Oct 2022 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
- 17 Oct 2022 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.